Berry Genomics Co.,Ltd, a genomics company, develops and commercializes technologies for the life sciences and clinical applications in China. The company offers NGS- based tests for various genetic diseases and cancers from preconception to adulthood; WES test for inherited pathogenic mutations in the GCH1 gene associated with the metabolic disease Dopa-responsive dystonia; CNV-Seq test for indicating translocation at the end of chromosomes 2 and 8; RNA-Seq test to demonstrate the photo-induced protein dimerization of plant cryptochromes; and WGS test for genome wide detection of DNA variants, including SNP, CNV, Indel, and SV. It serves approximately 2,000 hospitals throughout Mainland China, Hong Kong, Macao, and Taiwan. The company serves various organizations and facilities, including hospitals, research institutions, universities, and corporations. Berry Genomics Co.,Ltd has a partnership with Personalis, Inc. The company was founded in 2010 and is headquartered in Beijing, China.
Оборотен капитал
2022
2021
2020
2019
2018
2017
Парични средства и инвестиции
333.56
417.89
629.31
411.49
423.62
411.63
Приемници
0.00
0.00
0.00
0.00
0.00
0.00
Инвентарна книга
230.95
233.88
180.27
421.86
205.74
107.50
Други
46.02
94.69
52.32
119.10
45.89
583.58
Общо текущи активи
1726.87
1906.58
2008.05
1852.59
1357.20
1102.71
Acc Payable
278.90
339.93
243.29
213.27
82.84
86.83
Краткосрочен дълг
216.69
199.98
123.48
11.27
0.00
29.26
Други текущи пасиви
209.13
228.67
189.67
225.18
142.54
88.49
Текущи пасиви
704.72
768.58
556.43
449.72
225.38
238.13
Капиталова структура
Всички числа в милиони
Общо активи
242,10 щ.д.
Общо задължения
133224410,06 щ.д.
Дългосрочен дълг
0,00 щ.д.
Парични средства и екви
26717672,42 щ.д.
Goodwill
0,00 щ.д.
Неразпределена печалба
-87977890,04 щ.д.
Обикновени акции
354,61 щ.д.
Стойност на предприятието
-25,68 щ.д.
Дивиденти за маса
Години
Q1
Q2
Q3
Q4
Общо
2001
0.000
0.078
0.000
0.000
0.078
Подобни запаси
Може да се интересувате и от
INSM
Insmed Incorporated.
19.24 USD
NASDAQ
ACAD
ACADIA Pharmaceuticals Inc..
23.9 USD
NASDAQ
ELYM
Eliem Therapeutics, Inc..
2.92 USD
NASDAQ
BGNE
BeiGene, Ltd..
223.48 USD
NASDAQ
VKTX
Viking Therapeutics, Inc..
21.96 USD
NASDAQ
PRTA
Prothena Corporation plc.
66.43 USD
NASDAQ
RETA
Reata Pharmaceuticals, Inc..
91.13 USD
NASDAQ
GTHX
G1 Therapeutics, Inc..
2.54 USD
NASDAQ
KURA
Kura Oncology, Inc..
13.5 USD
NASDAQ
CBAY
CymaBay Therapeutics, Inc..
8.98 USD
NASDAQ
ADVM
Adverum Biotechnologies, Inc..
1.14 USD
NASDAQ
Frequently Asked Question
Why is your stock tool better than competitors?
Numfin provides most features for free and gives you accurate and expert data about public companies. We also offer unique features like AI copilot that are not found on other platforms
Can I trust the data on your website and where do they come from?
Absolutely. We receive the data from our partners and other official sources, such as popular stock exchanges (NASDAQ, NYSE, and others), SEC.gov, and other official platforms. Our data provider, FinancialModeling, also provides information for portals like Moody's, Harvard, Chevron, and others. All this proves the accuracy and authority of the information.
Who creates the content on your website and is it approved by experts in finance and investing?
All financial data is received from our data provider and then verified by industry experts. Additionally, we use various AI tools like ChatGPT to present content in a user-friendly and well-structured manner.
What problem does your tool solve? Who is the target audience for your tool
Our main goal is to present accurate and expert information about public companies in a structured manner. We work with investors and financial professionals who have a long-term outlook. Our community consists of private investors, business owners, stock analysts, fund managers, and people who are interested in investing.
Why did you decide to create your tool?
While managing our own money, we searched for the best analytical tool to help us better analyze public companies. Most websites that provided analytics for professional investors were expensive, and the cheap tools were either limited in functionality or lacked valuable company data. Even worse, some of them presented incorrect numbers. As a result, we combined our experience in business, IT, and finance to create the most affordable and useful solution for investors and anyone interested in finance and stock analysis.
What is the difference between free and paid options? Should I buy Pro version from start or it's ok to have a free version?
Most features on our website are free so that many people can use it to analyze companies on the world's top stock exchanges. However, some features, such as our artificial intelligence chat, advanced analytics, filters, and storing of vast historical data, require additional servers from our end. Therefore, we rely on your support to keep this amazing project running. If you would like to experience the full potential of our service, we strongly recommend that you purchase the PRO version, which comes with a 30-day money-back guarantee
Who is your team and do they have enough experience?
You can read about our team here, or you can contact us at [email protected] for more information.
